BOULDER, Colo., Sept. 3, 2025 /PRNewswire/ — Edgewise Therapeutics, Inc. (“Edgewise” or the “Company”), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on August…
